Biogen Reports Q3 2024 Earnings with Revenue Decline and Mixed Performance Across Products
Biogen (BIIB) reported Q3 2024 earnings with a 3% decline in total revenue to $2.5 billion and a 6% drop in non-GAAP diluted EPS to $4.08. While non-GAAP operating income increased by 4%, revenue from key products like MS therapies and SPINRAZA declined, though some products like SKYCLARYS and the Rare Disease Franchise showed growth.
Tickers: $BIIB
Topics: Biogen Cost Initiatives Earnings EPS Pharmaceuticals R&D Revenue Decline